HomeAI · summaries
Storia in 8 fonti
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options, according to data from two phase 3 trials. During a symposium at the American Diabetes Association Scientific Sessions, researchers presented data from phase 3 trials investigating retatrutide (Eli Lilly), a once-weekly
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
- ·
morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
independent.co.uk
Eli Lilly’s new weight loss drug may also help sleep apnea according to Phase 3 data
The same trial also revealed retatrutide could offer substantial relief for knee osteoarthritis pain, reducing it by up to 73.1%
- ·
economictimes.indiatimes.com
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity.…
- ·
newsbytesapp.com
Eli Lilly's obesity drug shows promise in treating sleep apnea
Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.
- ·
gulfnews.com
New weekly diabetes jab cuts blood sugar, body weight in major trial
New weekly diabetes jab retatrutide cuts blood sugar and drives double-digit weight loss in type 2 diabetes patients in major phase 3 trial, The Lancet reports.
- ·
medpagetoday.com
Up to 40% of Diabetes Patients Achieved Normal HbA1c With Retatrutide
But its key advantage is in its weight reduction abilities
- ·
'Bariatric Surgery-Level' Weight Loss With Novel Triple-Agonist
Primary endpoints met in knee osteoarthritis and obstructive sleep apnea, too
- ·
Petrelintide, a novel amylin analog, induces 10% weight loss, very well tolerated
NEW ORLEANS — Weekly petrelintide demonstrated clinically meaningful weight loss through 42 weeks and was well tolerated among adults with obesity or overweight without diabetes,…
- ·
This triple-action jab can lower your blood sugar and weight
A new triple-action weekly injection, retatrutide, has demonstrated significant reductions in blood sugar and body weight during phase 3 clinical trials.
- ·
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes…